(-)-DHMEQ是一种选择性不可逆的NF-κB抑制剂，其通过共价结合半胱氨酸残基阻断NF-κB核易位，并表现出显著的抗炎与抗癌活性。
/
-25~-15℃避光保存，有效期3年。
[1] Sogabe, S., Naito, M., Arakawa, K., Okamoto, T., Ohtsuka, T., Onozawa, K., Takeda, Y., Tazawa, K., Togashi, M., & Suzuki, T. (2011). (-)-DHMEQ, a novel NF-κB inhibitor, induces apoptosis and enhances fludarabine activity in richter's syndrome cells. Leukemia Research, 35(9), 1208–1213. https://doi.org/10.1016/j.leukres.2011.05.003
[2]Watanabe M, Ohsugi T, Shoda M, Ishida T, Aizawa S, Maruyama-Nagai M, Utsunomiya A, Koga S, Yamada Y, Kamihira S, Okayama A, Kikuchi H, Uozumi K, Yamaguchi K, Higashihara M, Umezawa K, Watanabe T, Horie R. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-kappaB, as a strategy for chemoprevention and therapy of adult T-cell leukemia. Blood. 2005 Oct 1;106(7):2462-71. doi: 10.1182/blood-2004-09-3646. Epub 2005 Jun 14. PMID: 15956280.
